A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Of Oral RPC1063 As Induction And Maintenance Therapy For Moderate To Severe Ulcerative Colitis
Principal Investigator(s)
Email for information
Funded by
Geneva
Research Start Date
Status
Active
Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis. The objectives of this trial are to demonstrate the efficacy of RPC1063 versus placebo on induction of clinical remission and maintenance therapy on clinical remission. The trial is composed of 2 periods: Induction and Maintenance. Patients will be entered into the trial in 2 separate cohorts through the Induction Period and those patients in clinical response at the end of the Induction Period will proceed through to the Maintenance Period. Patients who participate in this trial may also qualify to participate in an optional Open-Label Extension trial.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.